Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03098329 · ClinicalTrials.gov registry record · NA
Check it: A New Approach to Controlling Chlamydia Transmission in Young People
A NA study, sponsored by Tulane University.
- Completed
- Registry status
- NA
- Development phase
- 1,907
- Enrollment target
NCT03098329: Completed NA study, sponsored by Tulane University.
NCT03098329 is a NA study that has completed, run by Tulane University. The registered enrollment target is 1,907 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03098329, a NA study, has completed, sponsored by Tulane University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,907 participants
- Enrollment target
Study Summary
This study, named "Check it," is a bundled program for African American (AA) men ages 15-24 that includes community testing for chlamydia and gonorrhea, expedited treatment for subjects who test positive and their female sexual contacts, and rescreening for these two sexually transmitted infections.
Primary Outcome
primary outcome
Interventions
- OTHER Ct/GC screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,907 participants |
| Start Date | 2017-05-22 |
| Est. Completion | 2021-05-28 |
| Phase | NA |
What the finished NCT03098329 record still lists
NCT03098329 is an interventional study that assigns participants to a tested intervention. Its 1,907 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (36% higher).
The record links to 0 conditions, and to 1 intervention - of which Ct/GC screening is the first listed.
NCT03098329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03098329 about?
NCT03098329 is a clinical study titled "Check it: A New Approach to Controlling Chlamydia Transmission in Young People". This study, named "Check it," is a bundled program for African American (AA) men ages 15-24 that includes community testing for chlamydia and gonorrhea, expedited treatment for subjects who test positive and their female sexual contacts, and rescreening for these two sexually transmitted infections.
What is the current status of trial NCT03098329?
This trial is currently completed. It is a NA study. The enrollment target is 1,907 participants. The study started on 2017-05-22. Estimated completion is 2021-05-28.
What interventions are being tested in trial NCT03098329?
The interventions under investigation include: Ct/GC screening (OTHER).
Who is sponsoring clinical trial NCT03098329?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03098329's enrollment target sits among peer trials
1,907 55th of 2000 higher than 1,946 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06799117 · 1,912 participants · NA
Adaptive Decision Support for Addiction Treatment Master
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI